We are analyzing https://link.springer.com/article/10.1007/s00280-005-0098-0.

Title:
Beyond simple castration: targeting the molecular basis of treatment resistance in advanced prostate cancer | Cancer Chemotherapy and Pharmacology
Description:
Over the past 20 years, research on hormonal treatments for prostate cancer focused on maximizing androgen ablation through combination therapy. Unfortunately, maximal androgen ablation increases treatment-related side effects and expense and has not significantly prolonged time to androgen-independent (AI) progression. Intermittent androgen suppression (IAS) is based on the hypothesis that if tumor cells surviving androgen withdrawal can be forced along a normal pathway of differentiation by androgen replacement, then apoptotic potential might be restored, androgen dependence may be prolonged and progression to androgen independence may be delayed. Observations from animal model studies suggest that progression to androgen independence is delayed by IAS and this strategy is now being evaluated in phase III trials. Another strategy for improving therapies in advanced prostate cancer involves targeting genes that are activated by either androgen withdrawal or chemotherapy to delay or prevent the emergence of the resistant AI phenotype. Targeted inhibition of stress-associated increases in gene expression precipitated by androgen withdrawal or chemotherapy may enhance treatment-induced apoptosis and delay progression to AI disease. Proteins fulfilling these criteria include antiapoptotic members of the Bcl-2 protein family, clusterin, Hsp27, and IGFBP-2 and IGFBP-5. The purpose of this paper is to review the rationale and progress in using targeted gene therapies to enhance tumor cell death after androgen withdrawal or taxane chemotherapy. Antisense oligonucleotides offer one approach to target genes involved in cancer progression, especially those not amenable to small molecule or antibody inhibition. The current status and future direction of several antisense oligonucleotides that have potential clinical use in cancer are also reviewed.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Health & Fitness
Education
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We find it hard to spot revenue streams.

Earning money isn't the goal of every website; some are designed to offer support or promote social causes. People have different reasons for creating websites. This might be one such reason. Link.springer.com might be plotting its profit, but the way they're doing it isn't detectable yet.

Keywords {🔍}

cancer, google, scholar, prostate, pubmed, cas, article, androgen, gleave, therapy, intermittent, res, miyake, progression, suppression, antisense, urol, goldenberg, patients, study, treatment, advanced, model, chemotherapy, chi, tumor, clin, human, phase, bcl, bruchovsky, group, research, hormonal, androgenindependent, cells, withdrawal, gene, rennie, trial, urology, lncap, castration, molecular, resistance, apoptosis, clusterin, cell, proc, oncol,

Topics {✒️}

month download article/chapter targeted gene therapies antisense oligonucleotide-based therapeutics canadian uro-oncology group antisense bcl-2 oligonucleotide target genes involved prostate-specific antigen gene hideaki miyake & kim chi hormone-independent prostate cancer asco post-meeting abstracts node-positive prostate cancer antisense bcl-2 oligodeoxynucleotides androgen-independent prostate cancer hormone-resistant prostate cancer testosterone-repressed prostate message-2 androgen-independent cancer progression human cancer cells enhance treatment-induced apoptosis heat shock proteins bcl-2 protein family human prostate cancer full article pdf de reijke tm prostate cancer cells tumor cells grown article cancer chemotherapy privacy choices/manage cookies advanced prostate cancer 2′methoxyethyl phosphorothioate antisense prostate cancer prior androgen ablation therapy metastatic prostate cancer androgen-independent regulation androgen-independent recurrence antisense oligonucleotides offer spontaneous mutation rate antisense clusterin oligonucleotides prostate cancer focused prostate cancer managed prostate cancer rates intermittent androgen suppression prospective multicenter study anti-androgen therapy androgen deprivation therapy intermittent androgen deprivation maximizing androgen ablation intermittent hormonal therapy related subjects lopes de menezes maximum androgen blockade

Questions {❓}

Conroy SE, Latchman DS (1996) Do heat shock proteins have a role in breast cancer?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Beyond simple castration: targeting the molecular basis of treatment resistance in advanced prostate cancer
         description:Over the past 20 years, research on hormonal treatments for prostate cancer focused on maximizing androgen ablation through combination therapy. Unfortunately, maximal androgen ablation increases treatment-related side effects and expense and has not significantly prolonged time to androgen-independent (AI) progression. Intermittent androgen suppression (IAS) is based on the hypothesis that if tumor cells surviving androgen withdrawal can be forced along a normal pathway of differentiation by androgen replacement, then apoptotic potential might be restored, androgen dependence may be prolonged and progression to androgen independence may be delayed. Observations from animal model studies suggest that progression to androgen independence is delayed by IAS and this strategy is now being evaluated in phase III trials. Another strategy for improving therapies in advanced prostate cancer involves targeting genes that are activated by either androgen withdrawal or chemotherapy to delay or prevent the emergence of the resistant AI phenotype. Targeted inhibition of stress-associated increases in gene expression precipitated by androgen withdrawal or chemotherapy may enhance treatment-induced apoptosis and delay progression to AI disease. Proteins fulfilling these criteria include antiapoptotic members of the Bcl-2 protein family, clusterin, Hsp27, and IGFBP-2 and IGFBP-5. The purpose of this paper is to review the rationale and progress in using targeted gene therapies to enhance tumor cell death after androgen withdrawal or taxane chemotherapy. Antisense oligonucleotides offer one approach to target genes involved in cancer progression, especially those not amenable to small molecule or antibody inhibition. The current status and future direction of several antisense oligonucleotides that have potential clinical use in cancer are also reviewed.
         datePublished:2005-11-05T00:00:00Z
         dateModified:2005-11-05T00:00:00Z
         pageStart:47
         pageEnd:57
         sameAs:https://doi.org/10.1007/s00280-005-0098-0
         keywords:
            Androgen independence
            Clusterin
            Hsp27
            Intermittent therapy
            bcl-2
            Oncology
            Pharmacology/Toxicology
            Cancer Research
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-005-0098-0/MediaObjects/280_2005_98_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-005-0098-0/MediaObjects/280_2005_98_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-005-0098-0/MediaObjects/280_2005_98_Fig3_HTML.gif
         isPartOf:
            name:Cancer Chemotherapy and Pharmacology
            issn:
               1432-0843
               0344-5704
            volumeNumber:56
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Martin Gleave
               affiliation:
                     name:Vancouver General Hospital
                     address:
                        name:Vancouver General Hospital, Vancouver, Canada
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Hideaki Miyake
               affiliation:
                     name:Vancouver General Hospital
                     address:
                        name:Vancouver General Hospital, Vancouver, Canada
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Kim Chi
               affiliation:
                     name:Vancouver General Hospital
                     address:
                        name:Vancouver General Hospital, Vancouver, Canada
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Beyond simple castration: targeting the molecular basis of treatment resistance in advanced prostate cancer
      description:Over the past 20 years, research on hormonal treatments for prostate cancer focused on maximizing androgen ablation through combination therapy. Unfortunately, maximal androgen ablation increases treatment-related side effects and expense and has not significantly prolonged time to androgen-independent (AI) progression. Intermittent androgen suppression (IAS) is based on the hypothesis that if tumor cells surviving androgen withdrawal can be forced along a normal pathway of differentiation by androgen replacement, then apoptotic potential might be restored, androgen dependence may be prolonged and progression to androgen independence may be delayed. Observations from animal model studies suggest that progression to androgen independence is delayed by IAS and this strategy is now being evaluated in phase III trials. Another strategy for improving therapies in advanced prostate cancer involves targeting genes that are activated by either androgen withdrawal or chemotherapy to delay or prevent the emergence of the resistant AI phenotype. Targeted inhibition of stress-associated increases in gene expression precipitated by androgen withdrawal or chemotherapy may enhance treatment-induced apoptosis and delay progression to AI disease. Proteins fulfilling these criteria include antiapoptotic members of the Bcl-2 protein family, clusterin, Hsp27, and IGFBP-2 and IGFBP-5. The purpose of this paper is to review the rationale and progress in using targeted gene therapies to enhance tumor cell death after androgen withdrawal or taxane chemotherapy. Antisense oligonucleotides offer one approach to target genes involved in cancer progression, especially those not amenable to small molecule or antibody inhibition. The current status and future direction of several antisense oligonucleotides that have potential clinical use in cancer are also reviewed.
      datePublished:2005-11-05T00:00:00Z
      dateModified:2005-11-05T00:00:00Z
      pageStart:47
      pageEnd:57
      sameAs:https://doi.org/10.1007/s00280-005-0098-0
      keywords:
         Androgen independence
         Clusterin
         Hsp27
         Intermittent therapy
         bcl-2
         Oncology
         Pharmacology/Toxicology
         Cancer Research
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-005-0098-0/MediaObjects/280_2005_98_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-005-0098-0/MediaObjects/280_2005_98_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00280-005-0098-0/MediaObjects/280_2005_98_Fig3_HTML.gif
      isPartOf:
         name:Cancer Chemotherapy and Pharmacology
         issn:
            1432-0843
            0344-5704
         volumeNumber:56
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Martin Gleave
            affiliation:
                  name:Vancouver General Hospital
                  address:
                     name:Vancouver General Hospital, Vancouver, Canada
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Hideaki Miyake
            affiliation:
                  name:Vancouver General Hospital
                  address:
                     name:Vancouver General Hospital, Vancouver, Canada
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Kim Chi
            affiliation:
                  name:Vancouver General Hospital
                  address:
                     name:Vancouver General Hospital, Vancouver, Canada
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Cancer Chemotherapy and Pharmacology
      issn:
         1432-0843
         0344-5704
      volumeNumber:56
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Vancouver General Hospital
      address:
         name:Vancouver General Hospital, Vancouver, Canada
         type:PostalAddress
      name:Vancouver General Hospital
      address:
         name:Vancouver General Hospital, Vancouver, Canada
         type:PostalAddress
      name:Vancouver General Hospital
      address:
         name:Vancouver General Hospital, Vancouver, Canada
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Martin Gleave
      affiliation:
            name:Vancouver General Hospital
            address:
               name:Vancouver General Hospital, Vancouver, Canada
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Hideaki Miyake
      affiliation:
            name:Vancouver General Hospital
            address:
               name:Vancouver General Hospital, Vancouver, Canada
               type:PostalAddress
            type:Organization
      name:Kim Chi
      affiliation:
            name:Vancouver General Hospital
            address:
               name:Vancouver General Hospital, Vancouver, Canada
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Vancouver General Hospital, Vancouver, Canada
      name:Vancouver General Hospital, Vancouver, Canada
      name:Vancouver General Hospital, Vancouver, Canada
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(201)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.77s.

LINK . SPRINGER . COM {}